Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
NCT07552584

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

Led by Vejle Hospital · Updated on 2026-05-06

1000

Participants Needed

2

Research Sites

417 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease). Patients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest. The primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting. The secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.

CONDITIONS

Official Title

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with COPD
  • Age 50 years or older
  • Former or current smoker
  • Speaks and understands Danish
  • Able to give informed consent to participate
Not Eligible

You will not qualify if you...

  • Had a chest CT scan within the past 6 months
  • Received active cancer treatment within the past year (except for non-melanoma skin cancer and carcinoma in situ cervicis uteri)
  • Diagnosed with cancer within the past year (except for non-melanoma skin cancer and carcinoma in situ cervicis uteri)
  • Has symptoms suspicious of cancer (except non-melanoma skin cancer and carcinoma in situ cervicis uteri)
  • Has a condition that prevents diagnostic workup or treatment of lung cancer
  • Does not have Eboks (electronic communication with Danish authorities)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Lillebaelt Hospital Vejle, University Hospital of Southern Denmark

Vejle, Denmark, 7100

Actively Recruiting

2

General practices, Vejle area

Vejle, Denmark

Actively Recruiting

Loading map...

Research Team

S

Sara Witting Christensen WC Wen, MD, PhD

CONTACT

L

Lene Horsted, Study nurse

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here